5-bromo-2-(oxiran-2-yl)pyridine | 1335050-95-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-2-(oxiran-2-yl)pyridine
• 英文别名: Pyridine, 5-bromo-2-(2-oxiranyl)-
• CAS: 1335050-95-7
• 化学式: C₇H₆BrNO
• 分子量: 200.035
• InChiKey: QYOYKFCCKGWXGH-UHFFFAOYSA-N

物化性质

• 沸点：
  265.7±35.0 °C(Predicted)
• 密度：
  1.696±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-1-Boc-3-羟甲基哌嗪 、 5-bromo-2-(oxiran-2-yl)pyridine 以 甲醇 为溶剂， 反应 1.0h， 以66%的产率得到tert-butyl (3S)-4-(2-(5-bromopyridin-2-yl)-2-hydroxyethyl)-3-(hydroxymethyl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] NEW HETEROCYCLIC COMPOUNDS
  [FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES

  摘要：

  该发明提供了具有一般式（I）的新杂环化合物，其中R1、R2、X和Y如本文所定义，包括这些化合物的组合物，制造这些化合物的过程以及使用这些化合物的方法。

  公开号：

  WO2021005034A1

文献信息

• INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180148411A1

  公开（公告）日：2018-05-31

  The present invention relates to compounds of general formula I, wherein the groups R, R 1 , R 2 , R 3 , m and n are as defined herein, which compounds have valuable pharmacological properties, in particular their ability to bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular type 2 diabetes. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

  本发明涉及一般式I的化合物，其中R、R1、R2、R3、m和n的基团如本文所定义，这些化合物具有有价值的药理学特性，特别是它们与GPR40受体结合并调节其活性的能力。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。此外，本发明涉及用于合成一般式I化合物的新型中间体。
• [EN] BENZYLOXYPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] ACIDES BENZYLOXYPYRIDYLCYCLOPROPANECARBOXYLIQUES, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018138029A1

  公开（公告）日：2018-08-02

  The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式（I）的化合物，其中R、R1、R2、R3、m和n组分的定义如权利要求书1中所述，具有有价值的药理特性，特别是结合GPR40受体并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• [EN] BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICALCOMPOSITIONS AND USES THEREOF<br/>[FR] ACIDES BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIQUES, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS ASSOCIÉES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018138027A1

  公开（公告）日：2018-08-02

  The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式（I）的化合物，其中R，R1，R2，R3，m和n组团如权利要求书1中所定义，具有有价值的药理学特性，特别是与GPR40受体结合并调节其活性。这些化合物适用于治疗和预防可以受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
  申请人：Gravestock Barry Michael

  公开号：US20080021071A1

  公开（公告）日：2008-01-24

  Compounds of formula (I), as well as pharmaceutically-acceptable salts and pro-drugs thereof, are disclosed wherein R 1 , R 2 , R 3 , and R 4 are defined herein. Also disclosed are processes for making compounds of formula (I) as well as methods of using compounds of formula (I) for treating bacterial infections.

  本发明揭示了化学式(I)的化合物，以及其药学上可接受的盐和前药，其中R1、R2、R3和R4在此定义。本发明还揭示了制备化学式(I)化合物的方法，以及使用化学式(I)化合物治疗细菌感染的方法。
• Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10125101B2

  公开（公告）日：2018-11-13

  The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are as defined herein, which compounds have valuable pharmacological properties, in particular their ability to bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular type 2 diabetes. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

  本发明涉及通式 I 的化合物、 其中基团 R、R1、R2、R3、m 和 n 如本文所定义，这些化合物具有宝贵的药理特性，特别是它们与 GPR40 受体结合并调节其活性的能力。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，特别是 2 型糖尿病。此外，本发明还涉及可用于合成式 I 化合物的新型中间体。